新闻发布
Novasep presents the second successful year of its ‘back to basics’ strategy and preliminary 2015 financial results
- Solid 7% sales growth in 2015 (€266m)
- Strong EBITDA growth with a 15% increase to €31m
Novasep adds synthesis and kilo lab extensions to US facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers
Novasep and Advanced Biotherapeutics Consulting team up on Adeno-Associated Virus (AAV) vectors
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy
Novasep and CPI advance innovation in UK biopharmaceutical manufacturing
Novasep’s BioSC® Lab continuous biochromatography equipment will enable CPI to disseminate next-generation downstream processes
Novasep appoints two executives to further strengthen its management team
Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director
Novasep reports strong 2014 full year results
- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy